IP Library Granted Patent US 11,958,902
Granted Patent B2
US 11,958,902 · App. 16/939,883 · Granted Apr 16, 2024

Anti-TIGIT antibodies

Inventors: Sybil M. G. Williams (Wayland, MA); Wolfgang Seghezzi (Mountain View, CA); Laurence Fayadat-Dilman (Sunnyvale, CA); Linda Liang (Mountain View, CA); Veronica Juan (Redwood City, CA)
Assignee: Merck Sharp & Dohme LLC
C07K16/2803A61K39/3955A61K39/39558A61K39/39566A61P31/00A61K2039/572C07K2317/24C07K2317/34C07K2317/76C07K2317/92C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,958,902
App. No.
16/939,883
Granted
Apr 16, 2024
Kind
B2
Abstract

The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.

Claims (7)

1. A method of producing an antibody or antigen binding fragment thereof comprising:

a. culturing a host cell comprising a polynucleotide encoding a heavy chain and/or a light chain of an antibody or antigen binding fragment thereof under conditions favorable to expression of the polynucleotide; and

b. optionally, recovering the antibody or antigen binding fragment thereof from the host cell and/or culture medium,

wherein the antibody or antigen binding fragment thereof binds to human T cell immunoreceptor with Ig and ITIM domains (TIGIT), and

wherein the antibody or antigen binding fragment thereof is selected from the group consisting of:

(i) an antibody or antigen binding fragment thereof comprising: a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3, 45, 46, or 47, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:6, 57, 58, 59, 60, 61, or 62; and

(ii) an antibody or antigen binding fragment thereof comprising: a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:17, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:18, 81, 82, 83, 84, 85, 86, 87, or 88, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:19, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:20, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:21, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:22.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2023
From: WILLIAMS, SYBIL M.G.; SEGHEZZI, WOLFGANG; FAYADAT-DILMAN, LAURENCE; LIANG, LINDA; JUAN, VERONICA
To: MERCK SHARP & DOHME CORP.
Reel/Frame 065715/0583 →
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →